We are live on ! Find out more
KRYS icon

Krystal Biotech

76 hedge funds and large institutions have $397M invested in Krystal Biotech in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more capital inflows, than outflows

Capital inflows: $137M | Capital outflows: $36.4M

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

33% more funds holding

Funds holding: 57 → 76 (+19)

11.48% more ownership

Funds ownership: 46.53% → 58.01% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
76
Holders Change
+19
Holders Change %
+33.33%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
29
Increased
26
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KRYS Hedge Fund Activity: Q2 2019 in Review

76 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2019, worth a combined $397M — up 78% from $223M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KRYS positions and 11 closed out — a net gain of 18 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Redmile Group, adding an estimated $24.7M. The largest seller was Great Point Partners, exiting entirely with an estimated $16.2M sold.

  • 76 institutional investors held Krystal Biotech (KRYS) as of Q2 2019, up from 57 in Q1 2019.
  • Funds reported $397M of Krystal Biotech stock for Q2 2019, up 78% quarter-over-quarter.
  • 29 funds opened new Krystal Biotech positions in Q2 2019 and 11 closed out, a net change of +18 holders.
  • The largest Krystal Biotech buyer in Q2 2019 was Redmile Group, an estimated $24.7M added.
  • The largest Krystal Biotech seller in Q2 2019 was Great Point Partners, an estimated $16.2M sold.

Based on aggregated 13F filings for Q2 2019.